{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:44:08Z","timestamp":1792014248529,"version":"4.4.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40263-026-01331-7","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:25:55Z","timestamp":1788949555000},"page":"1445-1458","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cognitive Side Effects of Antiseizure Medications in Adults with Epilepsy: An Update with a Focus on New Therapeutic Agents"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9415-3395","authenticated-orcid":false,"given":"Marco","family":"Mula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"1331_CR1","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","volume":"11","author":"P Perucca","year":"2012","unstructured":"Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11:792\u2013802. https:\/\/doi.org\/10.1016\/S1474-4422(12)70153-9.","journal-title":"Lancet Neurol"},{"key":"1331_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/00023210-200923020-00003","volume":"23","author":"M Mula","year":"2009","unstructured":"Mula M, Trimble MR. Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors. CNS Drugs. 2009;23:121\u201337.","journal-title":"CNS Drugs"},{"key":"1331_CR3","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","volume":"35","author":"W L\u00f6scher","year":"2021","unstructured":"L\u00f6scher W, Klein P. The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond. CNS Drugs. 2021;35:935\u201363. https:\/\/doi.org\/10.1007\/s40263-021-00827-8.","journal-title":"CNS Drugs"},{"key":"1331_CR4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.yebeh.2012.09.018","volume":"26","author":"P Perucca","year":"2013","unstructured":"Perucca P, Mula M. Antiepileptic drug effects on mood and behavior: molecular targets. Epilepsy Behav. 2013;26:440\u20139. https:\/\/doi.org\/10.1016\/j.yebeh.2012.09.018.","journal-title":"Epilepsy Behav"},{"key":"1331_CR5","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/sj.mp.4001087","volume":"7","author":"NB Farber","year":"2002","unstructured":"Farber NB, Jiang X-P, Heinkel C, Nemmers B. Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol Psychiatry. 2002;7:726\u201333. https:\/\/doi.org\/10.1038\/sj.mp.4001087.","journal-title":"Mol Psychiatry"},{"key":"1331_CR6","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1212\/01.WNL.0000056637.37509.C6","volume":"60","author":"M Mula","year":"2003","unstructured":"Mula M, Trimble MR, Thompson P, Sander JWAS. Topiramate and word-finding difficulties in patients with epilepsy. Neurology. 2003;60:1104\u20137.","journal-title":"Neurology"},{"key":"1331_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/epi.12550","volume":"55","author":"RS Fisher","year":"2014","unstructured":"Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55:475\u201382. https:\/\/doi.org\/10.1111\/epi.12550.","journal-title":"Epilepsia"},{"key":"1331_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1528-1167.2009.02195.x","volume":"51","author":"J Taylor","year":"2010","unstructured":"Taylor J, Kolamunnage-Dona R, Marson AG, Smith PEM, Aldenkamp AP, Baker GA. Patients with epilepsy: cognitively compromised before the start of antiepileptic drug treatment? Epilepsia. 2010;51:48\u201356. https:\/\/doi.org\/10.1111\/j.1528-1167.2009.02195.x.","journal-title":"Epilepsia"},{"key":"1331_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.seizure.2015.01.018","volume":"26","author":"J-A Witt","year":"2015","unstructured":"Witt J-A, Helmstaedter C. Cognition in the early stages of adult epilepsy. Seizure. 2015;26:65\u20138. https:\/\/doi.org\/10.1016\/j.seizure.2015.01.018.","journal-title":"Seizure"},{"key":"1331_CR10","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/S0140-6736(12)61455-X","volume":"380","author":"JJ Lin","year":"2012","unstructured":"Lin JJ, Mula M, Hermann BP. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet. 2012;380:1180\u201392. https:\/\/doi.org\/10.1016\/S0140-6736(12)61455-X.","journal-title":"Lancet"},{"key":"1331_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1212\/CON.0000000000001123","volume":"28","author":"M Mula","year":"2022","unstructured":"Mula M, Coleman H, Wilson SJ. Neuropsychiatric and cognitive comorbidities in epilepsy. Continuum (Minneap Minn). 2022;28:457\u201382. https:\/\/doi.org\/10.1212\/CON.0000000000001123.","journal-title":"Continuum (Minneap Minn)"},{"key":"1331_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110272","volume":"164","author":"D Samanta","year":"2025","unstructured":"Samanta D. Cognitive and behavioral impact of antiseizure medications, neuromodulation, ketogenic diet, and surgery in Lennox-Gastaut syndrome: a comprehensive review. Epilepsy Behav. 2025;164:110272. https:\/\/doi.org\/10.1016\/j.yebeh.2025.110272.","journal-title":"Epilepsy Behav"},{"key":"1331_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ejpn.2014.05.008","volume":"18","author":"G Coppola","year":"2014","unstructured":"Coppola G, Besag F, Cusmai R, Dulac O, Kluger G, Moavero R, et al. Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines. Eur J Paediatr Neurol. 2014;18:685\u201390. https:\/\/doi.org\/10.1016\/j.ejpn.2014.05.008.","journal-title":"Eur J Paediatr Neurol"},{"key":"1331_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107445","volume":"112","author":"FF Operto","year":"2020","unstructured":"Operto FF, Verrotti A, Marrelli A, Ciuffini R, Coppola G, Pastorino GMG, et al. Cognitive, adaptive, and behavioral effects of adjunctive rufinamide in Lennox-Gastaut syndrome: a prospective observational clinical study. Epilepsy Behav. 2020;112:107445. https:\/\/doi.org\/10.1016\/j.yebeh.2020.107445.","journal-title":"Epilepsy Behav"},{"key":"1331_CR15","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1528-1167.2006.00589.x","volume":"47","author":"AP Aldenkamp","year":"2006","unstructured":"Aldenkamp AP, Alpherts WC. The effect of the new antiepileptic drug rufinamide on cognitive functions. Epilepsia. 2006;47:1153\u20139. https:\/\/doi.org\/10.1111\/j.1528-1167.2006.00589.x.","journal-title":"Epilepsia"},{"key":"1331_CR16","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1345\/aph.1M679","volume":"44","author":"CS Wisniewski","year":"2010","unstructured":"Wisniewski CS. Rufinamide: a new antiepileptic medication for the treatment of seizures associated with lennox-gastaut syndrome. Ann Pharmacother. 2010;44:658\u201367. https:\/\/doi.org\/10.1345\/aph.1M679.","journal-title":"Ann Pharmacother"},{"key":"1331_CR17","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1111\/bcp.12479","volume":"78","author":"AMS Alsaad","year":"2014","unstructured":"Alsaad AMS, Koren G. Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials. Br J Clin Pharmacol. 2014;78:1264\u201371. https:\/\/doi.org\/10.1111\/bcp.12479.","journal-title":"Br J Clin Pharmacol"},{"key":"1331_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.70075","volume":"52","author":"S Abbas","year":"2025","unstructured":"Abbas S, Parveen A, Ashraf W, Anjum SMM, Mushtaq RMZ, Alqahtani F, et al. Rufinamide mitigates seizures and behavioural deficits via BDNF\/TrkB modulation and oxidative stress reduction in pentylenetetrazole-kindled mice. Clin Exp Pharmacol Physiol. 2025;52:e70075. https:\/\/doi.org\/10.1111\/1440-1681.70075.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"1331_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.cbi.2018.03.007","volume":"286","author":"BH Chen","year":"2018","unstructured":"Chen BH, Ahn JH, Park JH, Song M, Kim H, Lee T-K, et al. Rufinamide, an antiepileptic drug, improves cognition and increases neurogenesis in the aged gerbil hippocampal dentate gyrus via increasing expressions of IGF-1, IGF-1R and p-CREB. Chem Biol Interact. 2018;286:71\u20137. https:\/\/doi.org\/10.1016\/j.cbi.2018.03.007.","journal-title":"Chem Biol Interact"},{"key":"1331_CR20","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/dmcn.13704","volume":"60","author":"KA Myers","year":"2018","unstructured":"Myers KA, Lightfoot P, Patil SG, Cross JH, Scheffer IE. Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study. Dev Med Child Neurol. 2018;60:574\u20138. https:\/\/doi.org\/10.1111\/dmcn.13704.","journal-title":"Dev Med Child Neurol"},{"key":"1331_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/0883073818811538","volume":"34","author":"EP Y\u0131ld\u0131z","year":"2019","unstructured":"Y\u0131ld\u0131z EP, Ozkan MU, Uzunhan TA, Bekta\u015f G, Tatl\u0131 B, Ayd\u0131nl\u0131 N, et al. Efficacy of Stiripentol and the clinical outcome in Dravet syndrome. J Child Neurol. 2019;34:33\u20137. https:\/\/doi.org\/10.1177\/0883073818811538.","journal-title":"J Child Neurol"},{"key":"1331_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106535","volume":"170","author":"M Yamada","year":"2021","unstructured":"Yamada M, Suzuki K, Matsui D, Inoue Y, Ohtsuka Y. Long-term safety and effectiveness of stiripentol in patients with Dravet syndrome: interim report of a post-marketing surveillance study in Japan. Epilepsy Res. 2021;170:106535. https:\/\/doi.org\/10.1016\/j.eplepsyres.2020.106535.","journal-title":"Epilepsy Res"},{"key":"1331_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.yebeh.2017.12.017","volume":"82","author":"E Andermann","year":"2018","unstructured":"Andermann E, Biton V, Benbadis SR, Shneker B, Shah AK, Carre\u00f1o M, et al. Psychiatric and cognitive adverse events: a pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures. Epilepsy Behav. 2018;82:119\u201327. https:\/\/doi.org\/10.1016\/j.yebeh.2017.12.017.","journal-title":"Epilepsy Behav"},{"key":"1331_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yebeh.2018.01.029","volume":"81","author":"S J\u00f3\u017awiak","year":"2018","unstructured":"J\u00f3\u017awiak S, Veggiotti P, Moreira J, Gama H, Rocha F, Soares-da-Silva P. Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures. Epilepsy Behav. 2018;81:1\u201311. https:\/\/doi.org\/10.1016\/j.yebeh.2018.01.029.","journal-title":"Epilepsy Behav"},{"key":"1331_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jns.2019.04.040","volume":"402","author":"CP Doherty","year":"2019","unstructured":"Doherty CP, Rheims S, Assenza G, Boero G, Chaves J, McMurray R, et al. Eslicarbazepine acetate in epilepsy patients with psychiatric comorbidities and intellectual disability: clinical practice findings from the Euro-Esli study. J Neurol Sci. 2019;402:88\u201399. https:\/\/doi.org\/10.1016\/j.jns.2019.04.040.","journal-title":"J Neurol Sci"},{"key":"1331_CR26","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.yebeh.2010.04.022","volume":"18","author":"D Milovan","year":"2010","unstructured":"Milovan D, Almeida L, Romach MK, Nunes T, Rocha JF, Sokowloska M, et al. Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. Epilepsy Behav. 2010;18:366\u201373. https:\/\/doi.org\/10.1016\/j.yebeh.2010.04.022.","journal-title":"Epilepsy Behav"},{"key":"1331_CR27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.yebeh.2019.02.034","volume":"94","author":"KJ Meador","year":"2019","unstructured":"Meador KJ, Seliger J, Boyd A, Razavi B, Falco-Walter J, Le S, et al. Comparative neuropsychological effects of carbamazepine and eslicarbazepine acetate. Epilepsy Behav. 2019;94:151\u20137. https:\/\/doi.org\/10.1016\/j.yebeh.2019.02.034.","journal-title":"Epilepsy Behav"},{"key":"1331_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40268-017-0197-5","volume":"17","author":"GL Galiana","year":"2017","unstructured":"Galiana GL, Gauthier AC, Mattson RH. Eslicarbazepine acetate: a new improvement on a classic drug family for the treatment of partial-onset seizures. Drugs R D. 2017;17:329\u201339. https:\/\/doi.org\/10.1007\/s40268-017-0197-5.","journal-title":"Drugs R D"},{"key":"1331_CR29","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.yebeh.2012.11.052","volume":"26","author":"C Helmstaedter","year":"2013","unstructured":"Helmstaedter C, Witt J-A. The longer-term cognitive effects of adjunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting. Epilepsy Behav. 2013;26:182\u20137. https:\/\/doi.org\/10.1016\/j.yebeh.2012.11.052.","journal-title":"Epilepsy Behav"},{"key":"1331_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107464","volume":"113","author":"T Wu","year":"2020","unstructured":"Wu T, Chuang Y-C, Huang H-C, Lim S-N, Hsieh PF, Lee W-T, et al. A prospective, multicenter, noninterventional study in Taiwan to evaluate the safety and tolerability of lacosamide as adjunctive therapy for epilepsy in clinical practice. Epilepsy Behav. 2020;113:107464. https:\/\/doi.org\/10.1016\/j.yebeh.2020.107464.","journal-title":"Epilepsy Behav"},{"key":"1331_CR31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/ane.12372","volume":"131","author":"DM IJff","year":"2015","unstructured":"IJff DM, van Veenendaal TM, Majoie HJM, de Louw AJA, Jansen JFA, Aldenkamp AP. Cognitive effects of lacosamide as adjunctive therapy in refractory epilepsy. Acta Neurol Scand. 2015;131:347\u201354. https:\/\/doi.org\/10.1111\/ane.12372.","journal-title":"Acta Neurol Scand"},{"key":"1331_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.yebeh.2016.04.049","volume":"61","author":"ME Lancman","year":"2016","unstructured":"Lancman ME, Fertig EJ, Trobliger RW, Perrine K, Myers L, Iyengar SS, et al. The effects of lacosamide on cognition, quality-of-life measures, and quality of life in patients with refractory partial epilepsy. Epilepsy Behav. 2016;61:27\u201333. https:\/\/doi.org\/10.1016\/j.yebeh.2016.04.049.","journal-title":"Epilepsy Behav"},{"key":"1331_CR33","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.yebeh.2016.07.007","volume":"62","author":"KJ Meador","year":"2016","unstructured":"Meador KJ, Loring DW, Boyd A, Echauz J, LaRoche S, Velez-Ruiz N, et al. Randomized double-blind comparison of cognitive and EEG effects of lacosamide and carbamazepine. Epilepsy Behav. 2016;62:267\u201375. https:\/\/doi.org\/10.1016\/j.yebeh.2016.07.007.","journal-title":"Epilepsy Behav"},{"key":"1331_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108598","volume":"128","author":"M Pozzi","year":"2022","unstructured":"Pozzi M, Zanotta N, Epifanio R, Baldelli S, Cattaneo D, Clementi E, et al. Lacosamide effectiveness and tolerability in patients with drug-resistant epilepsy and severe disability under polytherapy: therapy optimization as emerging from an observational study. Epilepsy Behav. 2022;128:108598. https:\/\/doi.org\/10.1016\/j.yebeh.2022.108598.","journal-title":"Epilepsy Behav"},{"key":"1331_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108401","volume":"125","author":"E Zwierzy\u0144ska","year":"2021","unstructured":"Zwierzy\u0144ska E, Pietrzak B. The antiepileptic drug lacosamide and memory - a preclinial study. Epilepsy Behav. 2021;125:108401. https:\/\/doi.org\/10.1016\/j.yebeh.2021.108401.","journal-title":"Epilepsy Behav"},{"key":"1331_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.696946","volume":"12","author":"FF Operto","year":"2021","unstructured":"Operto FF, Vivenzio V, Scuoppo C, Padovano C, Roccella M, Quatrosi G, et al. Perampanel and visuospatial skills in children with epilepsy. Front Neurol. 2021;12:696946. https:\/\/doi.org\/10.3389\/fneur.2021.696946.","journal-title":"Front Neurol"},{"key":"1331_CR37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.seizure.2021.12.001","volume":"94","author":"J-A Witt","year":"2022","unstructured":"Witt J-A, Helmstaedter C. The impact of perampanel on cognition: a systematic review of studies employing standardized tests in patients with epilepsy. Seizure. 2022;94:107\u201311. https:\/\/doi.org\/10.1016\/j.seizure.2021.12.001.","journal-title":"Seizure"},{"key":"1331_CR38","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/epi.13279","volume":"57","author":"KJ Meador","year":"2016","unstructured":"Meador KJ, Yang H, Pi\u00f1a-Garza JE, Laurenza A, Kumar D, Wesnes KA. Cognitive effects of adjunctive perampanel for partial-onset seizures: a randomized trial. Epilepsia. 2016;57:243\u201351. https:\/\/doi.org\/10.1111\/epi.13279.","journal-title":"Epilepsia"},{"key":"1331_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.yebeh.2018.03.029","volume":"83","author":"JE Pi\u00f1a-Garza","year":"2018","unstructured":"Pi\u00f1a-Garza JE, Lagae L, Villanueva V, Renfroe JB, Laurenza A, Williams B, et al. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures. Epilepsy Behav. 2018;83:50\u20138. https:\/\/doi.org\/10.1016\/j.yebeh.2018.03.029.","journal-title":"Epilepsy Behav"},{"key":"1331_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13020372","volume":"13","author":"G Scorrano","year":"2024","unstructured":"Scorrano G, Lattanzi S, Salpietro V, Giannini C, Chiarelli F, Matricardi S. The cognitive and behavioural effects of perampanel in children with neurodevelopmental disorders: a systematic review. J Clin Med. 2024;13:372. https:\/\/doi.org\/10.3390\/jcm13020372.","journal-title":"J Clin Med"},{"key":"1331_CR41","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.2147\/NDT.S410858","volume":"19","author":"X Yue","year":"2023","unstructured":"Yue X, Liu X-M, Chen J, Chen H-Y, Tan Q-Q, Zhou Y. The efficacy and cognitive impact of perampanel monotherapy in patients with self-limited epilepsy with centrotemporal spikes: a retrospective analysis. Neuropsychiatr Dis Treat. 2023;19:1263\u201371. https:\/\/doi.org\/10.2147\/NDT.S410858.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1331_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110268","volume":"164","author":"KJ Meador","year":"2025","unstructured":"Meador KJ, Seliger J, Le S, Li Y, Razavi B, Falco-Walter J, et al. Cognitive and behavioral effects of perampanel 4 mg daily dose. Epilepsy Behav. 2025;164:110268. https:\/\/doi.org\/10.1016\/j.yebeh.2025.110268.","journal-title":"Epilepsy Behav"},{"key":"1331_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106879","volume":"103","author":"FF Operto","year":"2020","unstructured":"Operto FF, Pastorino GMG, Mazza R, Di Bonaventura C, Matricardi S, Verrotti A, et al. Perampanel tolerability in children and adolescents with focal epilepsy: effects on behavior and executive functions. Epilepsy Behav. 2020;103:106879. https:\/\/doi.org\/10.1016\/j.yebeh.2019.106879.","journal-title":"Epilepsy Behav"},{"issue":"Suppl 1","key":"1331_CR44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/epi.12504","volume":"55","author":"F Rugg-Gunn","year":"2014","unstructured":"Rugg-Gunn F. Adverse effects and safety profile of perampanel: a review of pooled data. Epilepsia. 2014;55(Suppl 1):13\u20135. https:\/\/doi.org\/10.1111\/epi.12504.","journal-title":"Epilepsia"},{"key":"1331_CR45","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1528-1167.2010.02746.x","volume":"52","author":"KJ Meador","year":"2011","unstructured":"Meador KJ, Gevins A, Leese PT, Otoul C, Loring DW. Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam. Epilepsia. 2011;52:264\u201372. https:\/\/doi.org\/10.1111\/j.1528-1167.2010.02746.x.","journal-title":"Epilepsia"},{"key":"1331_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.seizure.2018.09.016","volume":"62","author":"J-A Witt","year":"2018","unstructured":"Witt J-A, Elger CE, Helmstaedter C. Short-term and longer-term effects of brivaracetam on cognition and behavior in a naturalistic clinical setting-Preliminary data. Seizure. 2018;62:49\u201354. https:\/\/doi.org\/10.1016\/j.seizure.2018.09.016.","journal-title":"Seizure"},{"key":"1331_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2024.107482","volume":"209","author":"D Bourikas","year":"2025","unstructured":"Bourikas D, Koch J, de la Loge C, Dimova S, Elmoufti S, Moseley B, et al. Long-term efficacy and tolerability of brivaracetam in pediatric patients with focal-onset seizures and cognitive or learning comorbidities: post hoc analysis of an open-label trial. Epilepsy Res. 2025;209:107482. https:\/\/doi.org\/10.1016\/j.eplepsyres.2024.107482.","journal-title":"Epilepsy Res"},{"key":"1331_CR48","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1007\/s00415-024-12253-z","volume":"271","author":"JP Szaflarski","year":"2024","unstructured":"Szaflarski JP, Besson H, D\u2019Souza W, Faught E, Klein P, Reuber M, et al. Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis. J Neurol. 2024;271:3169\u201385. https:\/\/doi.org\/10.1007\/s00415-024-12253-z.","journal-title":"J Neurol"},{"key":"1331_CR49","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s43440-023-00564-3","volume":"76","author":"E Zwierzy\u0144ska","year":"2024","unstructured":"Zwierzy\u0144ska E, Pietrzak B. The impact of brivaracetam on cognitive processes and anxiety in various experimental models. Pharmacol Rep. 2024;76:86\u201397. https:\/\/doi.org\/10.1007\/s43440-023-00564-3.","journal-title":"Pharmacol Rep"},{"key":"1331_CR50","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.yebeh.2018.11.032","volume":"90","author":"E Theochari","year":"2019","unstructured":"Theochari E, Cock H, Lozsadi D, Galtrey C, Arevalo J, Mula M. Brivaracetam in adults with drug-resistant epilepsy and psychiatric comorbidities. Epilepsy Behav. 2019;90:129\u201331. https:\/\/doi.org\/10.1016\/j.yebeh.2018.11.032.","journal-title":"Epilepsy Behav"},{"key":"1331_CR51","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.seizure.2022.02.007","volume":"96","author":"A Snoeren","year":"2022","unstructured":"Snoeren A, Majoie MHJM, Fasen KCFM, Ijff DM. Brivaracetam for the treatment of refractory epilepsy in patients with prior exposure to levetiracetam: a retrospective outcome analysis. Seizure. 2022;96:102\u20137. https:\/\/doi.org\/10.1016\/j.seizure.2022.02.007.","journal-title":"Seizure"},{"key":"1331_CR52","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/14737175.2019.1631160","volume":"19","author":"Y Makke","year":"2019","unstructured":"Makke Y, Abou-Khalil B. Brivaracetam efficacy and safety in focal epilepsy. Expert Rev Neurother. 2019;19:955\u201364. https:\/\/doi.org\/10.1080\/14737175.2019.1631160.","journal-title":"Expert Rev Neurother"},{"key":"1331_CR53","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.2147\/NDT.S143548","volume":"15","author":"AM Feyissa","year":"2019","unstructured":"Feyissa AM. Brivaracetam in the treatment of epilepsy: a review of clinical trial data. Neuropsychiatr Dis Treat. 2019;15:2587\u2013600. https:\/\/doi.org\/10.2147\/NDT.S143548.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1331_CR54","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2147\/TCRM.S145630","volume":"15","author":"IE Overwater","year":"2019","unstructured":"Overwater IE, Rietman AB, van Eeghen AM, de Wit MCY. Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives. Ther Clin Risk Manag. 2019;15:951\u20135. https:\/\/doi.org\/10.2147\/TCRM.S145630.","journal-title":"Ther Clin Risk Manag"},{"key":"1331_CR55","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388:2153\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(16)31419-2.","journal-title":"Lancet"},{"key":"1331_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpsychires.2016.03.008","volume":"78","author":"E Russo","year":"2016","unstructured":"Russo E, Leo A, Crupi R, Aiello R, Lippiello P, Spiga R, et al. Everolimus improves memory and learning while worsening depressive- and anxiety-like behavior in an animal model of depression. J Psychiatr Res. 2016;78:1\u201310. https:\/\/doi.org\/10.1016\/j.jpsychires.2016.03.008.","journal-title":"J Psychiatr Res"},{"key":"1331_CR57","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.yebeh.2019.04.044","volume":"97","author":"RC Martin","year":"2019","unstructured":"Martin RC, Gaston TE, Thompson M, Ampah SB, Cutter G, Bebin EM, et al. Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy. Epilepsy Behav. 2019;97:105\u201310. https:\/\/doi.org\/10.1016\/j.yebeh.2019.04.044.","journal-title":"Epilepsy Behav"},{"key":"1331_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107558","volume":"114","author":"B Metternich","year":"2021","unstructured":"Metternich B, Wagner K, Geiger MJ, Hirsch M, Schulze-Bonhage A, Klotz KA. Cognitive and behavioral effects of cannabidiol in patients with treatment-resistant epilepsy. Epilepsy Behav. 2021;114:107558. https:\/\/doi.org\/10.1016\/j.yebeh.2020.107558.","journal-title":"Epilepsy Behav"},{"key":"1331_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107299","volume":"111","author":"MD Thompson","year":"2020","unstructured":"Thompson MD, Martin RC, Grayson LP, Ampah SB, Cutter G, Szaflarski JP, et al. Cognitive function and adaptive skills after a one-year trial of cannabidiol (CBD) in a pediatric sample with treatment-resistant epilepsy. Epilepsy Behav. 2020;111:107299. https:\/\/doi.org\/10.1016\/j.yebeh.2020.107299.","journal-title":"Epilepsy Behav"},{"key":"1331_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1749260","volume":"16","author":"G Pes\u00e1ntez R\u00edos","year":"2025","unstructured":"Pes\u00e1ntez R\u00edos G, Perucca E, Striano P, Caraballo R, Pes\u00e1ntez R\u00edos X, Pascual-Pascual SI, et al. Epilepsy, neuroinflammation and cannabidiol what do we know thus far? Front Pharmacol. 2025;16:1749260. https:\/\/doi.org\/10.3389\/fphar.2025.1749260.","journal-title":"Front Pharmacol"},{"key":"1331_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108316","volume":"124","author":"TE Gaston","year":"2021","unstructured":"Gaston TE, Martin RC, Szaflarski JP. Cannabidiol (CBD) and cognition in epilepsy. Epilepsy Behav. 2021;124:108316. https:\/\/doi.org\/10.1016\/j.yebeh.2021.108316.","journal-title":"Epilepsy Behav"},{"key":"1331_CR62","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/epi.14629","volume":"60","author":"PH Patra","year":"2019","unstructured":"Patra PH, Barker-Haliski M, White HS, Whalley BJ, Glyn S, Sandhu H, et al. Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models. Epilepsia. 2019;60:303\u201314. https:\/\/doi.org\/10.1111\/epi.14629.","journal-title":"Epilepsia"},{"key":"1331_CR63","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40263-024-01063-6","volume":"38","author":"PJ Serrano-Castro","year":"2024","unstructured":"Serrano-Castro PJ, Ram\u00edrez-Garc\u00eda T, Cabezudo-Garcia P, Garcia-Martin G, De La Parra J. Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study. CNS Drugs. 2024;38:141\u201351. https:\/\/doi.org\/10.1007\/s40263-024-01063-6.","journal-title":"CNS Drugs"},{"key":"1331_CR64","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.seizure.2022.10.004","volume":"102","author":"E Schuetz","year":"2022","unstructured":"Schuetz E, Wagner K, Metternich B, Papadopoulou G, Kravalis K, Heers M, et al. Effects of cenobamate on cognitive performance of epilepsy patients. Seizure. 2022;102:129\u201333. https:\/\/doi.org\/10.1016\/j.seizure.2022.10.004.","journal-title":"Seizure."},{"key":"1331_CR65","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40263-025-01196-2","volume":"39","author":"J-A Witt","year":"2025","unstructured":"Witt J-A, Badr M, Surges R, von Wrede R, Helmstaedter C. The effects of cenobamate and its dosage on cognition: a retrospective longitudinal study in 84 individuals with epilepsy. CNS Drugs. 2025;39:893\u2013902. https:\/\/doi.org\/10.1007\/s40263-025-01196-2.","journal-title":"CNS Drugs"},{"key":"1331_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109605","volume":"151","author":"GL Krauss","year":"2024","unstructured":"Krauss GL, Chung SS, Ferrari L, Stern S, Rosenfeld WE. Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies. Epilepsy Behav. 2024;151:109605. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109605.","journal-title":"Epilepsy Behav"},{"key":"1331_CR67","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","volume":"394","author":"L Lagae","year":"2019","unstructured":"Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394:2243\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(19)32500-0.","journal-title":"Lancet"},{"key":"1331_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.106989","volume":"105","author":"P Martin","year":"2020","unstructured":"Martin P, de Witte PAM, Maurice T, Gammaitoni A, Farfel G, Galer B. Fenfluramine acts as a positive modulator of sigma-1 receptors. Epilepsy Behav. 2020;105:106989. https:\/\/doi.org\/10.1016\/j.yebeh.2020.106989.","journal-title":"Epilepsy Behav"},{"key":"1331_CR69","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s40265-023-01881-w","volume":"83","author":"JE Frampton","year":"2023","unstructured":"Frampton JE. Fenfluramine: a review in Dravet and Lennox-Gastaut syndromes. Drugs. 2023;83:923\u201334. https:\/\/doi.org\/10.1007\/s40265-023-01881-w.","journal-title":"Drugs"},{"key":"1331_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1192022","volume":"14","author":"J Sourbron","year":"2023","unstructured":"Sourbron J, Lagae L. Fenfluramine: a plethora of mechanisms? Front Pharmacol. 2023;14:1192022. https:\/\/doi.org\/10.3389\/fphar.2023.1192022.","journal-title":"Front Pharmacol"},{"key":"1331_CR71","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/dmcn.14822","volume":"63","author":"M Gogou","year":"2021","unstructured":"Gogou M, Cross JH. Fenfluramine as antiseizure medication for epilepsy. Dev Med Child Neurol. 2021;63:899\u2013907. https:\/\/doi.org\/10.1111\/dmcn.14822.","journal-title":"Dev Med Child Neurol"},{"key":"1331_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110753","volume":"173","author":"KG Knupp","year":"2025","unstructured":"Knupp KG, Scheffer IE, Schoonjans A-S, Sullivan J, Lagae L, Auvin S, et al. Final analysis from an open-label extension study of fenfluramine for the treatment of seizures in Lennox-Gastaut syndrome: long-term impact on patients and caregivers. Epilepsy Behav. 2025;173:110753. https:\/\/doi.org\/10.1016\/j.yebeh.2025.110753.","journal-title":"Epilepsy Behav"},{"key":"1331_CR73","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1474-4422(22)00077-1","volume":"21","author":"EMP Knight","year":"2022","unstructured":"Knight EMP, Amin S, Bahi-Buisson N, Benke TA, Cross JH, Demarest ST, et al. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2022;21:417\u201327. https:\/\/doi.org\/10.1016\/S1474-4422(22)00077-1.","journal-title":"Lancet Neurol"},{"key":"1331_CR74","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40272-024-00670-6","volume":"27","author":"SM Hoy","year":"2025","unstructured":"Hoy SM. Ganaxolone: a review in epileptic seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. Paediatr Drugs. 2025;27:111\u20138. https:\/\/doi.org\/10.1007\/s40272-024-00670-6.","journal-title":"Paediatr Drugs"},{"key":"1331_CR75","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/14656566.2024.2342413","volume":"25","author":"P Khan","year":"2024","unstructured":"Khan P, Saini S, Hussain S, Majid H, Gupta S, Agarwal N. A systematic review and meta-analysis on efficacy and safety of ganaxolone in epilepsy. Expert Opin Pharmacother. 2024;25:621\u201332. https:\/\/doi.org\/10.1080\/14656566.2024.2342413.","journal-title":"Expert Opin Pharmacother"},{"key":"1331_CR76","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejpn.2024.06.005","volume":"51","author":"J Downs","year":"2024","unstructured":"Downs J, Jacoby P, Specchio N, Cross H, Amin S, Bahi-Buisson N, et al. Effects of ganaxolone on non-seizure outcomes in CDKL5 deficiency disorder: double-blind placebo-controlled randomized trial. Eur J Paediatr Neurol. 2024;51:140\u20136. https:\/\/doi.org\/10.1016\/j.ejpn.2024.06.005.","journal-title":"Eur J Paediatr Neurol"},{"key":"1331_CR77","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1111\/ene.16050","volume":"30","author":"C Dusanter","year":"2023","unstructured":"Dusanter C, Houot M, Mere M, Denos M, Samson S, Herlin B, et al. Cognitive effect of antiseizure medications in medial temporal lobe epilepsy. Eur J Neurol. 2023;30:3692\u2013702. https:\/\/doi.org\/10.1111\/ene.16050.","journal-title":"Eur J Neurol"},{"key":"1331_CR78","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.yebeh.2008.10.017","volume":"14","author":"H Arif","year":"2009","unstructured":"Arif H, Buchsbaum R, Weintraub D, Pierro J, Resor SR, Hirsch LJ. Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behav. 2009;14:202\u20139. https:\/\/doi.org\/10.1016\/j.yebeh.2008.10.017.","journal-title":"Epilepsy Behav"},{"key":"1331_CR79","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.seizure.2018.04.015","volume":"58","author":"C Meschede","year":"2018","unstructured":"Meschede C, Witt J-A, Rademacher M, von Wrede RD, Elger CE, Helmstaedter C. Evaluating the longer-term cognitive effects of adjunctive perampanel compared to lacosamide in a naturalistic outpatient setting. Seizure. 2018;58:141\u20136. https:\/\/doi.org\/10.1016\/j.seizure.2018.04.015.","journal-title":"Seizure"},{"key":"1331_CR80","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40272-021-00448-0","volume":"23","author":"FMC Besag","year":"2021","unstructured":"Besag FMC, Vasey MJ. Neurocognitive effects of antiseizure medications in children and adolescents with epilepsy. Paediatr Drugs. 2021;23:253\u201386. https:\/\/doi.org\/10.1007\/s40272-021-00448-0.","journal-title":"Paediatr Drugs"},{"key":"1331_CR81","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.yebeh.2010.02.011","volume":"18","author":"C Helmstaedter","year":"2010","unstructured":"Helmstaedter C, Witt J-A. Cognitive outcome of antiepileptic treatment with levetiracetam versus carbamazepine monotherapy: a non-interventional surveillance trial. Epilepsy Behav. 2010;18:74\u201380. https:\/\/doi.org\/10.1016\/j.yebeh.2010.02.011.","journal-title":"Epilepsy Behav"},{"key":"1331_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.106906","volume":"104","author":"RJ Quon","year":"2020","unstructured":"Quon RJ, Mazanec MT, Schmidt SS, Andrew AS, Roth RM, MacKenzie TA, et al. Antiepileptic drug effects on subjective and objective cognition. Epilepsy Behav. 2020;104:106906. https:\/\/doi.org\/10.1016\/j.yebeh.2020.106906.","journal-title":"Epilepsy Behav"},{"key":"1331_CR83","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1007\/s00415-018-8971-z","volume":"265","author":"RA Sarkis","year":"2018","unstructured":"Sarkis RA, Goksen Y, Mu Y, Rosner B, Lee JW. Cognitive and fatigue side effects of anti-epileptic drugs: an analysis of phase III add-on trials. J Neurol. 2018;265:2137\u201342. https:\/\/doi.org\/10.1007\/s00415-018-8971-z.","journal-title":"J Neurol"},{"issue":"Suppl 4","key":"1331_CR84","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1046\/j.1528-1157.44.s4.3.x","volume":"44","author":"AP Aldenkamp","year":"2003","unstructured":"Aldenkamp AP, De Krom M, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia. 2003;44(Suppl 4):21\u20139. https:\/\/doi.org\/10.1046\/j.1528-1157.44.s4.3.x.","journal-title":"Epilepsia"},{"key":"1331_CR85","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1007\/s10072-024-07606-5","volume":"45","author":"J Shafiyev","year":"2024","unstructured":"Shafiyev J, Karada\u015f \u00d6. The assessment of the impact of antiepileptic drugs on cognitive functions via N-200\/P-300 potentials and neuropsychological measures. Neurol Sci. 2024;45:5011\u201321. https:\/\/doi.org\/10.1007\/s10072-024-07606-5.","journal-title":"Neurol Sci"},{"key":"1331_CR86","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1111\/epi.16576","volume":"61","author":"C Meschede","year":"2020","unstructured":"Meschede C, Witt J-A, Br\u00f6mling S, Moskau-Hartmann S, Rademacher M, Surges R, et al. Changes in cognition after introduction or withdrawal of zonisamide versus topiramate in epilepsy patients: a retrospective study using Bayes statistics. Epilepsia. 2020;61:1481\u201390. https:\/\/doi.org\/10.1111\/epi.16576.","journal-title":"Epilepsia"},{"key":"1331_CR87","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2165\/00023210-199605050-00005","volume":"5","author":"R K\u00e4lvi\u00e4inen","year":"1996","unstructured":"K\u00e4lvi\u00e4inen R, \u00c4iki\u00e4 M, Riekkinen PJ. Cognitive adverse effects of antiepileptic drugs\u202f: incidence, mechanisms and therapeutic implications. CNS Drugs. 1996;5:358\u201368. https:\/\/doi.org\/10.2165\/00023210-199605050-00005.","journal-title":"CNS Drugs"},{"key":"1331_CR88","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awy022","volume":"141","author":"A Sen","year":"2018","unstructured":"Sen A, Capelli V, Husain M. Cognition and dementia in older patients with epilepsy. Brain. 2018;141:1592\u2013608. https:\/\/doi.org\/10.1093\/brain\/awy022.","journal-title":"Brain"},{"key":"1331_CR89","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2165\/00003495-200262040-00004","volume":"62","author":"L Brunbech","year":"2002","unstructured":"Brunbech L, Sabers A. Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: a comparative review of newer versus older agents. Drugs. 2002;62:593\u2013604. https:\/\/doi.org\/10.2165\/00003495-200262040-00004.","journal-title":"Drugs"},{"key":"1331_CR90","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/14656566.2017.1309025","volume":"18","author":"J-A Witt","year":"2017","unstructured":"Witt J-A, Helmstaedter C. How can we overcome neuropsychological adverse effects of antiepileptic drugs? Expert Opin Pharmacother. 2017;18:551\u20134. https:\/\/doi.org\/10.1080\/14656566.2017.1309025.","journal-title":"Expert Opin Pharmacother"},{"key":"1331_CR91","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(19)33064-8","volume":"395","author":"A Sen","year":"2020","unstructured":"Sen A, Jette N, Husain M, Sander JW. Epilepsy in older people. Lancet. 2020;395:735\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(19)33064-8.","journal-title":"Lancet"},{"key":"1331_CR92","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1212\/wnl.63.10_suppl_4.s40","volume":"63","author":"GK Bergey","year":"2004","unstructured":"Bergey GK. Initial treatment of epilepsy: special issues in treating the elderly. Neurology. 2004;63:S40\u20138. https:\/\/doi.org\/10.1212\/wnl.63.10_suppl_4.s40.","journal-title":"Neurology"},{"key":"1331_CR93","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/epi.17426","volume":"64","author":"L Piccenna","year":"2023","unstructured":"Piccenna L, O\u2019Dwyer R, Leppik I, Beghi E, Giussani G, Costa C, et al. Management of epilepsy in older adults: a critical review by the ILAE Task Force on Epilepsy in the elderly. Epilepsia. 2023;64:567\u201385. https:\/\/doi.org\/10.1111\/epi.17426.","journal-title":"Epilepsia"},{"key":"1331_CR94","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40266-018-0562-2","volume":"35","author":"GD Anderson","year":"2018","unstructured":"Anderson GD, Hakimian S. Pharmacokinetic factors to consider in the selection of antiseizure drugs for older patients with epilepsy. Drugs Aging. 2018;35:687\u201398. https:\/\/doi.org\/10.1007\/s40266-018-0562-2.","journal-title":"Drugs Aging"},{"key":"1331_CR95","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/14656566.2020.1843636","volume":"22","author":"A Rohracher","year":"2021","unstructured":"Rohracher A, Kalss G, Kuchukhidze G, Neuray C, Leitinger M, H\u00f6fler J, et al. New anti-seizure medication for elderly epilepsy patients\u2014a critical narrative review. Expert Opin Pharmacother. 2021;22:621\u201334. https:\/\/doi.org\/10.1080\/14656566.2020.1843636.","journal-title":"Expert Opin Pharmacother"},{"key":"1331_CR96","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40266-017-0465-7","volume":"34","author":"J Theitler","year":"2017","unstructured":"Theitler J, Brik A, Shaniv D, Berkovitch M, Gandelman-Marton R. Antiepileptic drug treatment in community-dwelling older patients with epilepsy: a retrospective observational study of old- versus new-generation antiepileptic drugs. Drugs Aging. 2017;34:479\u201387. https:\/\/doi.org\/10.1007\/s40266-017-0465-7.","journal-title":"Drugs Aging"},{"key":"1331_CR97","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1111\/epi.14432","volume":"59","author":"C Helmstaedter","year":"2018","unstructured":"Helmstaedter C, Beghi E, Elger CE, K\u00e4lvi\u00e4inen R, Malmgren K, May TW, et al. No proof of a causal relationship between antiepileptic drug treatment and incidence of dementia. Comment on: use of antiepileptic drugs and dementia risk\u2014an analysis of Finnish health register and German health insurance data. Epilepsia. 2018;59:1303\u20136. https:\/\/doi.org\/10.1111\/epi.14432.","journal-title":"Epilepsia"},{"key":"1331_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1128601","author":"Y-H Huang","year":"2023","unstructured":"Huang Y-H, Pan M-H, Yang H-I. The association between Gabapentin or Pregabalin use and the risk of dementia: an analysis of the National Health Insurance Research Database in Taiwan. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1128601.","journal-title":"Front Pharmacol"},{"key":"1331_CR99","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1111\/epi.16068","volume":"60","author":"N Lezaic","year":"2019","unstructured":"Lezaic N, Gore G, Josephson CB, Wiebe S, Jett\u00e9 N, Keezer MR. The medical treatment of epilepsy in the elderly: a systematic review and meta-analysis. Epilepsia. 2019;60:1325\u201340. https:\/\/doi.org\/10.1111\/epi.16068.","journal-title":"Epilepsia"},{"key":"1331_CR100","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S1474-4422(09)70240-6","volume":"8","author":"MJ Brodie","year":"2009","unstructured":"Brodie MJ, Elder AT, Kwan P. Epilepsy in later life. Lancet Neurol. 2009;8:1019\u201330. https:\/\/doi.org\/10.1016\/S1474-4422(09)70240-6.","journal-title":"Lancet Neurol"},{"key":"1331_CR101","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1111\/epi.16366","volume":"60","author":"S Lattanzi","year":"2019","unstructured":"Lattanzi S, Trinka E, Del Giovane C, Nardone R, Silvestrini M, Brigo F. Antiepileptic drug monotherapy for epilepsy in the elderly: a systematic review and network meta-analysis. Epilepsia. 2019;60:2245\u201354. https:\/\/doi.org\/10.1111\/epi.16366.","journal-title":"Epilepsia"},{"key":"1331_CR102","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2174\/1567205018666211126121529","volume":"18","author":"CS Musaeus","year":"2021","unstructured":"Musaeus CS, Nilsson C, Cooper C, Kramberger MG, Verdelho A, Stefanova E, et al. Pharmacological medical treatment of epilepsy in patients with dementia: a systematic review. Curr Alzheimer Res. 2021;18:689\u201394. https:\/\/doi.org\/10.2174\/1567205018666211126121529.","journal-title":"Curr Alzheimer Res"},{"key":"1331_CR103","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/epi4.70091","volume":"10","author":"C Faini","year":"2025","unstructured":"Faini C, Sen A, Romoli M. Effect of levetiracetam on cognition in patients with cognitive decline: a systematic review and meta-analysis of randomized controlled trials. Epilepsia Open. 2025;10:1253\u20139. https:\/\/doi.org\/10.1002\/epi4.70091.","journal-title":"Epilepsia Open"},{"key":"1331_CR104","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/S0140-6736(00)02149-8","volume":"355","author":"LJ Stephen","year":"2000","unstructured":"Stephen LJ, Brodie MJ. Epilepsy in elderly people. Lancet. 2000;355:1441\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(00)02149-8.","journal-title":"Lancet"},{"key":"1331_CR105","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1001\/jama.2022.3880","volume":"327","author":"AM Kanner","year":"2022","unstructured":"Kanner AM, Bicchi MM. Antiseizure medications for adults with epilepsy: a review. JAMA. 2022;327:1269\u201381. https:\/\/doi.org\/10.1001\/jama.2022.3880.","journal-title":"JAMA"},{"key":"1331_CR106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005399.pub3","volume":"2015","author":"CF Jackson","year":"2015","unstructured":"Jackson CF, Makin SM, Marson AG, Kerr M. Pharmacological interventions for epilepsy in people with intellectual disabilities. Cochrane Database Syst Rev. 2015;2015:CD005399. https:\/\/doi.org\/10.1002\/14651858.CD005399.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1","key":"1331_CR107","first-page":"1","volume":"42","author":"N Alvarez","year":"1998","unstructured":"Alvarez N, Besag F, Iivanainen M. Use of antiepileptic drugs in the treatment of epilepsy in people with intellectual disability. J Intellect Disabil Res. 1998;42(Suppl 1):1\u201315.","journal-title":"J Intellect Disabil Res"},{"key":"1331_CR108","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.braindev.2017.01.006","volume":"39","author":"R Moavero","year":"2017","unstructured":"Moavero R, Santarone ME, Galasso C, Curatolo P. Cognitive and behavioral effects of new antiepileptic drugs in pediatric epilepsy. Brain Dev. 2017;39:464\u20139. https:\/\/doi.org\/10.1016\/j.braindev.2017.01.006.","journal-title":"Brain Dev"},{"key":"1331_CR109","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s40263-024-01149-1","volume":"39","author":"LV Watkins","year":"2025","unstructured":"Watkins LV, Kinney M, Shankar R. Treatment of seizures in people with intellectual disability. CNS Drugs. 2025;39:161\u201383. https:\/\/doi.org\/10.1007\/s40263-024-01149-1.","journal-title":"CNS Drugs"},{"key":"1331_CR110","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(21)00247-6","volume":"397","author":"A Marson","year":"2021","unstructured":"Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397:1363\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(21)00247-6.","journal-title":"Lancet"},{"key":"1331_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109453","volume":"148","author":"JD Perkins","year":"2023","unstructured":"Perkins JD, Abdelmoneim MS, Wilkins SS, Kamran S, Mesraoua B, Melikyan G, et al. Dosage, time, and polytherapy dependent effects of different levetiracetam regimens on cognitive function. Epilepsy Behav. 2023;148:109453. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109453.","journal-title":"Epilepsy Behav"},{"key":"1331_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40263-023-01058-9","volume":"38","author":"C-Y Lin","year":"2024","unstructured":"Lin C-Y, Chang M-C, Jhou H-J. Effect of levetiracetam on cognition: a systematic review and meta-analysis of double-blind randomized placebo-controlled trials. CNS Drugs. 2024;38:1\u201314. https:\/\/doi.org\/10.1007\/s40263-023-01058-9.","journal-title":"CNS Drugs"},{"key":"1331_CR113","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.seizure.2008.11.001","volume":"18","author":"J Beavis","year":"2009","unstructured":"Beavis J, Meek A, Felce D, Kerr M. A prospective multi-centre open label study of the use of levetiracetam as add-on treatment in patients with epilepsy and intellectual disabilities. Seizure. 2009;18:279\u201384. https:\/\/doi.org\/10.1016\/j.seizure.2008.11.001.","journal-title":"Seizure"},{"key":"1331_CR114","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1053\/seiz.1999.0372","volume":"9","author":"BE Gidal","year":"2000","unstructured":"Gidal BE, Walker JK, Lott RS, Shaw R, Speth J, Marty KJ, et al. Efficacy of lamotrigine in institutionalized, developmentally disabled patients with epilepsy: a retrospective evaluation. Seizure. 2000;9:131\u20136. https:\/\/doi.org\/10.1053\/seiz.1999.0372.","journal-title":"Seizure"},{"key":"1331_CR115","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.yebeh.2004.07.009","volume":"5","author":"K Kelly","year":"2004","unstructured":"Kelly K, Stephen LJ, Brodie MJ. Levetiracetam for people with mental retardation and refractory epilepsy. Epilepsy Behav. 2004;5:878\u201383. https:\/\/doi.org\/10.1016\/j.yebeh.2004.07.009.","journal-title":"Epilepsy Behav"},{"key":"1331_CR116","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s40263-022-00969-3","volume":"36","author":"J-A Witt","year":"2022","unstructured":"Witt J-A, Widman G, Hansen N, von Wrede R, Elger CE, Helmstaedter C. Evaluation of a rapid topiramate titration scheme for the early detection of cognitive side effects. CNS Drugs. 2022;36:1325\u201330. https:\/\/doi.org\/10.1007\/s40263-022-00969-3.","journal-title":"CNS Drugs"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01331-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01331-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01331-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:44:20Z","timestamp":1792010660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01331-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":116,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1331"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01331-7","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"7 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the last 5\u00a0years, the author has received speaker fees from Eisai, Angelini, Bial, and UCB; consultancy fees from Angelini, Bial, Jazz, Elsevier and MEDSCAPE; royalties from Elsevier, Springer, and Cambridge University Press.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MM was the sole contributor to this article.","order":2,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}